Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice

Ann Neurol. 2020 Mar;87(3):480-485. doi: 10.1002/ana.25674. Epub 2020 Jan 22.

Abstract

Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480-485.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyltransferases / antagonists & inhibitors
  • Amidohydrolases / deficiency
  • Amidohydrolases / genetics
  • Animals
  • Aspartic Acid / analogs & derivatives*
  • Aspartic Acid / biosynthesis
  • Ataxia / complications
  • Ataxia / drug therapy
  • Atrophy / complications
  • Atrophy / drug therapy
  • Canavan Disease / complications
  • Canavan Disease / drug therapy*
  • Canavan Disease / pathology
  • Cerebellum / pathology
  • Female
  • Gene Knockdown Techniques
  • Infusions, Intraventricular
  • Male
  • Mice
  • Mutation
  • Oligonucleotides, Antisense / administration & dosage
  • Oligonucleotides, Antisense / therapeutic use*
  • Purkinje Cells / pathology
  • Rotarod Performance Test
  • Thalamus / pathology
  • Vacuoles / drug effects
  • Vacuoles / pathology

Substances

  • Oligonucleotides, Antisense
  • Aspartic Acid
  • N-acetylaspartate
  • Acetyltransferases
  • Shati protein, mouse
  • Amidohydrolases
  • aspartoacylase